Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Anthrogen logo — Molecular machines for human and planetary health.

Anthrogen

Molecular machines for human and planetary health.

Founded 2024 United States San Francisco, United States 10 employees Seed Total: $4.13M Biotechnology, Sustainability

General Information

Company Name Anthrogen
Founded Year 2024
Location United States San Francisco, United States
Employees 10
Industries Biotechnology, Sustainability
Funding Stage Seed
Business Model B2B, SaaS, API
Revenue Model Subscription, Usage Based, Licensing
Social

BounceWatch is an independent company data service, not affiliated with Anthrogen. To contact Anthrogen, visit anthrogen.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Anthrogen compare?

A PDF of Anthrogen and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Anthrogen soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Anthrogen

Anthrogen, founded in 2024, is an innovative startup at the intersection of Biotechnology and Sustainability, headquartered in the United States. The company is dedicated to constructing an AI-powered research lab for the accelerated discovery and development of biologics. Their approach addresses the long-standing issue of asymmetric verification in scientific discovery through the use of massively parallelized experimentation techniques.

Anthrogen's mission is encapsulated in their slogan: "Molecular machines for human and planetary health." Their cutting-edge work focuses on generating and validating molecular machines at the atomic scale, aiming for comprehensive control and impactful solutions.

In their latest funding round, Anthrogen secured a $4.00M seed investment on 01 November 2024, with backing from well-regarded investors like Y Combinator and Paul Graham, highlighting the confidence the investment community places in their potential.

Business keywords: AI-research, Biologics Discovery, Biomanufacturing, Synthetic Biology, Genetic Engineering, Bioengineering, Molecular Machines, Planetary Health, Massively Parallelized Experimentation, Bioindustrial Manufacturing, Verification in Discovery, Biotechnology Innovation, Environmental Impact

Services & Products

Protein generation and design using AI
Biologics discovery and development
Molecular machine validation
API for protein language models

Target Customers

Biotechnology companies Pharmaceutical companies Research laboratories Academia and educational institutions

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Seed $4.00M 2
Y Combinator Paul Graham
Y Combinator, Paul Graham
01 Nov 2024
Support Program Undisclosed 1
Y Combinator
Y Combinator
01 Jun 2024
Seed $130.00K 1
Y Combinator
Y Combinator
01 Jan 2024

Anthrogen Alternatives & Competitors

Anthrogen vs
Visolis
Visolis United States

Building decentralized supply chains for critical chemicals and fuels through biomanufacturing.

16 employees
Biotechnology, ESG

FAQ About Anthrogen

Molecular machines for human and planetary health.
Anthrogen was founded in 2024.
Anthrogen is headquartered in San Francisco, United States.
Anthrogen operates in Biotechnology and Sustainability. Its work centres on AI-research, Biologics Discovery, Biomanufacturing and Synthetic Biology. Its customers include Biotechnology companies, Pharmaceutical companies and Research laboratories.
Anthrogen has a B2B, SaaS and API business model. Its revenue comes from Subscription, Usage Based and Licensing.
Anthrogen has approximately 10 employees.
Anthrogen has completed 3 funding rounds, raising a total of $4.13M. The latest funding stage is Seed.
Anthrogen offers: Protein generation and design using AI, Biologics discovery and development, Molecular machine validation, API for protein language models.
Top alternatives and competitors to Anthrogen include Visolis. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Anthrogen and Visolis are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Anthrogen, https://bouncewatch.com/company/anthrogen-yc-s24, updated 2 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout